Fig. 6From: A Pronectin™ AXL-targeted first-in-class bispecific T cell engager (pAXLxCD3ε) for ovarian cancerA Immunohistochemistry staining of CD3 lymphocytes in explanted tumor from mice treated with vehicle + PBMCs. B Immunohistochemistry staining of CD3 lymphocytes in explanted tumor from mice treated with pAXLxCD3ε 0.1 mg/kg. Arrows indicate the stained CD3 lymphocytesBack to article page